


- 2 -

The following is a complete listing of all claims in the application, with an indication of the status of each:

Listing of claims:

1. (Previously presented) A compound of the general formula



where

m is an integer from 0 to 5;

n is an integer from 0 to 5;

R is C<sub>1</sub> to C<sub>7</sub> alkyl, cycloalkyl, phenyl, hydroxy, alkyl hydroxy, substituted phenyl, or CH<sub>2</sub>X<sup>1</sup>, where X<sup>1</sup> = H, Cl, Br, I or F;


R<sub>1</sub> is H, C<sub>1</sub> to C<sub>7</sub> alkyl, phenyl, or substituted phenyl;

R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are H or C<sub>1</sub> to C<sub>7</sub> alkyl, and R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> may be the same or different; and

X is CH<sub>2</sub> or a saturated or unsaturated C<sub>2</sub> carbon chain.


- 3 -

2. (Previously presented) A compound of formula




- 4 -

5. (Previously presented) A compound of formula




6. (Previously presented) A compound of formula



7. (Currently amended) A method of treatment of a condition or disorders related to cannabinoid-regulated systems in a patient in need thereof, wherein if said compound is an agonist of a CB1 receptor then said condition is selected from the group consisting of acute pain; chronic pain; inflammation; loss of appetite; convulsions; spasticity associated with multiple sclerosis; convulsions; epilepsy; and nausea and vomiting; and wherein if said compound is a silent antagonist of a CB1 receptor then said condition is selected from the group consisting of obesity; impaired cognition; and alcohol, tobacco, cocaine or marijuana dependence, comprising the step of

- 5 -

administering to said patient a quantity of a compound of formula



where

m is an integer from 0 to 5;

n is an integer from 0 to 5;

R is C<sub>1</sub> to C<sub>7</sub> alkyl, cycloalkyl, phenyl, hydroxy, alkyl hydroxy, substituted phenyl, or CH<sub>2</sub>X<sup>1</sup>, where X<sup>1</sup> = H, Cl, Br, I or F;

R<sub>1</sub> is H, C<sub>1</sub> to C<sub>7</sub> alkyl, phenyl, or substituted phenyl;

R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are H or C<sub>1</sub> to C<sub>7</sub> alkyl, and R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> may be the same or different; and


X is CH<sub>2</sub> or a saturated or unsaturated C<sub>2</sub> carbon chain,

in a quantity sufficient to ameliorate symptoms of said condition or disorder.

8-9. (Cancel)

10. (Currently amended) A method for treating pain in a patient comprising administering to said patient an effective dose of an agonist of a CB1 cannabinoid receptor wherein said agonist includes a sulfonamide moiety, and wherein said agonist has the chemical formula

- 6 -



where

m is an integer from 0 to 5;

n is an integer from 0 to 5;

R is C<sub>1</sub> to C<sub>7</sub> alkyl, cycloalkyl, phenyl, hydroxy, alkyl hydroxy, substituted phenyl, or CH<sub>2</sub>X<sup>1</sup>, where X<sup>1</sup> = H, Cl, Br, I or F;


R<sub>1</sub> is H, C<sub>1</sub> to C<sub>7</sub> alkyl, phenyl, or substituted phenyl;

R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are H or C<sub>1</sub> to C<sub>7</sub> alkyl, and R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> may be the same or different; and

X is CH<sub>2</sub> or a saturated or unsaturated C<sub>2</sub> carbon chain, with the proviso that if R is CH<sub>2</sub>, then X must be CH<sub>2</sub> or a saturated C<sub>2</sub> carbon chain.


11. (Cancel)

12. (Previously presented) The method of claim 10 wherein said agonist is selected from the group consisting of




- 7 -

and



13. (Currently amended) A method for treating nausea in a patient comprising administering to said patient an effective dose of an agonist of a CB1 cannabinoid receptor wherein said agonist includes a sulfonamide moiety, and wherein said agonist has the chemical formula



where

m is an integer from 0 to 5;

n is an integer from 0 to 5;

- 8 -

R is C<sub>1</sub> to C<sub>7</sub> alkyl, cycloalkyl, phenyl, hydroxy, alkyl hydroxy, substituted phenyl, or CH<sub>2</sub>X<sup>1</sup>, where X<sup>1</sup> = H, Cl, Br, I or F;


R<sub>1</sub> is F, C<sub>1</sub> to C<sub>7</sub> alkyl, phenyl, or substituted phenyl;

R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are H or C<sub>1</sub> to C<sub>7</sub> alkyl, and R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> may be the same or different; and


X is C<sub>1</sub> or a saturated or unsaturated C<sub>2</sub> carbon chain, with the proviso that if R is CH<sub>3</sub>, then X must be CH<sub>2</sub> or a saturated C<sub>2</sub> carbon chain.

14. (Cancel)

15. (Previous / presented) The method of claim 13, wherein said agonist is selected from the group consisting of




and



16. (Cancel)

- 9 -

17. (Currently amended) A method for treating obesity in a patient comprising administering to said patient an effective dose of a silent antagonist of a CB1 cannabinoid receptor wherein said silent antagonist includes a sulfonamide moiety, wherein said silent antagonist is



---

18-20. (Cancelled)